返回 A A A Font Size Receive E-mail Alerts Press Releases

Three Projects of MicroPort® Granted 2015-2016 Pudong Science and Technology Awards

[2017-11-24] 

Shanghai, China – On November 1, three projects of Shanghai MicroPort Medical (Group) Co., ("MicroPort®") were granted 2015-2016 Pudong Science and Technology Awards during the 2015-2016 Pudong Science and Technology Award Conference. The Project of "Development and Industrialization of Key Technologies in Minimally Invasive Treatment of Aortic Diseases" and the Project of "WILLIS® Intracranial Stent Graft System ("WILLIS®") Key Technology Development and Industrialization" respectively won Pudong Innovation Achievement Award for the year 2015 and 2016, and the Project of "Key Technologies and Industrialization Platform of Minimally Invasive and Implantable Medical Device" was granted the second prize of Pudong Science and Technology Progress Award.
 
Pudong Science and Technology Awards include Innovation Achievement Award and Science and Technology Progress Award. Innovation Achievement Award is specially given to the winners of the National or Shanghai Science and Technology Progress Award. The Pudong Science and Technology Progress Award is designed to honor scientific programs with sustainable achievements in scientific and technology innovation and high technology industrialization. During this award conference, 132 awards were given out for the year 2015, including 35 Innovation Achievement Awards and 97 Science and Technology Progress Awards, and 52 awards were granted for the year 2016, including 52 Innovation Achievement Awards and 84 Science and Technology Progress Awards.
 
The Project of "Development and Industrialization of Key Technologies in Minimally Invasive Treatment of Aortic Diseases," jointly developed by MicroPort®, its subsidiary MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular"), Beijing Anzhen Hospital of Capital Medical University, and Changhai Hospital of the Second Military Medical University, won the First Prize of Shanghai Science and Technology Progress Award in 2016. The project is a comprehensive solution for aortic diseases provided by MicroPort® Endovascular after years of research in interventional treatment of aortic diseases, including CRONUS™ Surgical Stent Graft System ("CRONUS™"), Hercules™-T Low Profile Stent-Graft ("HT-LP") and Delivery System, and Aegis™ Bifurcated Stent-Graft System ("Aegis™") and Delivery System, etc. These innovative stents graft have revolutionized the open surgery repair, and largely reduce the mortality rate of patients. It is estimated that more than 30,000 patients are saved by these products. Meanwhile, several products in this Project are the first-of-its kind among domestically developed products, successfully breaking the monopoly of imported products, which significantly lowered patients' economic burden.
 
The Project of "WILLIS® Intracranial Stent Graft System Key Technology Development and Industrialization" was developed by MicroPort NeuroTech (Shanghai) Co., Ltd. ("MicroPort® NeuroTech"). WILLIS® is the first stent graft system launched in China for the treatment of intracranial aneurysms, and is the first product in China that adopts the design of vascular reconstruction. It is composed of the stent and delivery system. With the procedure of vascular reconstruction, WILLIS® achieves complete occlusion of intracranial aneurysms, keeps the parental artery open, and leads to recovery in hemodynamics of the lesion area to achieve vascular reconstruction so as to attain the effect of treating aneurysm. Compared with the traditional method of stent-assisted coil embolization treatment, the procedure of vascular reconstruction using WILLIS® features small occupied effect, reduced risk of reoccurrence, and lower treatment cost. Previously, the project of "Research and Clinical Application of Noninvasive Imaging and Minimally Invasive Treatment of Intracranial Aneurysm and its Related Vascular," based on the clinical application of WILLIS®, was granted the second-class award of Science and Technology Achievements in 2014. It was completed by Professor Minghua Li of Shanghai Sixth People's Hospital, Zhiyong Xie, General Manager of MicroPort® NeuroTech and other professionals.
 
The Project of "Key Technologies and Industrialization Platform of Minimally Invasive and Implantable Medical Device", won the second prize of State Science and Technology Progress Award in 2015. The project is very special, as it was not awarded as a technology breakthrough or a new product through research and development, but as an overall innovation mode for an enterprise. By this unique innovation model and a comprehensive innovation mechanism, MicroPort® has gained over 1,800 issued patents around the world. Through years of growth and innovation, MicroPort® has become a premier medical solution provider covering 10 major medical disciplines including interventional cardiology, orthopedics, interventional radiology, electrophysiology, diabetes and endocrine management, surgical management, and others. With over 200 products currently approved for use in over 5,000 hospitals worldwide, MicroPort® is contributing to a better world through its life-saving medical therapies and quality-improving care devices being used in patients every 15 seconds. In the future, MicroPort® will continue to strive for innovation to promote the development of independent brands and focused on creating a sound environment for innovation and an efficient mechanism to cultivate innovative talents, to provide patients with rapidly increasing high-end medical products pioneering in China and throughout the whole world.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2017 MicroPort Scientific Corporation

CONTACT:
Amanda Zhang
Corporate Culture & Public Relations Director
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6989
Email: spokesperson@microport.com

 

[Prev]:MicroPort® Attends TCT to Display Firehawk® and Firesorb®
[Next]:FOXTROT™ NC PTCA Balloon Catheter Gains Regulatory Approval in Argentina